On the 20th local time, the results of the trial of the French pharmaceutical giant Servier by the Court of Appeal in Paris, France, were officially announced. The years-long lawsuit finally came to an end, with the court upholding Servier's convictions of "aggravated fraud" and "manslaughter" and convicting him of a total of more than 4300 million euros, about 33 yuanA fine of $600 million. This huge fine has once again raised public concern about drug safety.
It is understood that one of Servier's diabetes drugs has been abused as a drug for the past 33 years. This misconduct resulted in the deaths of at least 500 people and caused immense suffering to countless families. This incident not only plunged Servier into a whirlpool, but also made people question the effectiveness of the drug regulatory system.
This act of Servier is undoubtedly a betrayal of public trust. As a well-known pharmaceutical company, Servier should be responsible for the safety of the drugs it produces. However, the company used people's trust to bring a drug to market that had not been adequately tested, resulting in countless deaths and disabilities. Such acts are undoubtedly extremely serious acts of fraud and manslaughter.
The court's decision is a severe punishment for Servier and a wake-up call to the pharmaceutical industry. This incident once again reminds us that drug safety is a major matter related to the safety of people's lives, and no enterprise should ignore the safety and effectiveness of drugs under the pretext of pursuing profits. At the same time, the regulatory authorities should also strengthen the supervision of the pharmaceutical industry to ensure the safety and effectiveness of drugs.
This incident in Servier is a wake-up call for us. We should strengthen the supervision of the pharmaceutical industry to ensure that drugs are safe and effective. At the same time, we should also call on more people to pay attention to drug safety and jointly safeguard our health and life safety.